Introduction: Our collection centre performs an average of 50 bone marrow harvests per year (BMH) from altruistic healthy adult donors. BMH is recognized as a safe procedure but not entirely without risk of adverse events. There is a constant need to balance donor safety with recipient need and the increasing demands for larger donations. We decided to audit average Total Nucleated Cell counts (per ml) and benchmark against the National Marrow Donor Programme (NMDP) average. We also looked at the average drop in haemoglobin (Hb) and 30 day recovery as part of JACIE standard CM 6.3.9 (follow up of donors). Material (or patients) and methods: The medical assessment records and collection reports from 40 donors were reviewed and the TNC/ml x10 8 counts were calculated from the laboratory flow cytometry results. The data was also evaluated taking into consideration donor weight, gender, total number of requested cells vs collected cells and the total volume of BM harvested. An Hb level was taken 24 hours after BM donation. Results: From the sample of 40 BMH's (adult recipients) the average cell count of the collections was 0.177 x10 8 TNC per ml. The average volume of BM collected from our donors was 15 ml/kg (range 4.6-20 ml/kg). The average drop in Hb was 37 g/l (range 19-57) with post-op Hbs averaging 112 g/l (range 83-147 g/l). 5 donors had post-op Hb of less than 100 g/l. In another case a male donor had given just 15.5 ml/kg BM and yet his Hb dropped 56 g/l from 180 to 124 g/l. The figure shows the relation between volume of BM collected plus drop in Hb. Conclusion: The average TNC per ml collected at our centre compares well with figures quoted in published literature (0.16-0.22 x 10 8 TNC/ml 1 and by the NMDP (0.183 x10 8 TNC/ ml). NMDP quote that a 20 ml/kg BM collection drops the Hb by 40-50 g/l which could cause symptomatic anaemia. Our data showed most collections were under the NMDP standard (up to 20 ml marrow /donor kg) and smaller drops in Hb were seen.
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We conclude that we are achieving good cell counts from our donors and generally maintaining a post-procedure Hb of above 100 g/l. The information collected will help us inform donors about expected side effects such as fatigue and predict donors who may benefit from peri-operative iron supplementation. Data from day 30 blood counts will be reviewed to demonstrate recovery of Hb levels. References: 1. T. Introduction: HSCT patients are routinely treated with Cyclosporine A (CyA) post-transplant to prevent GvHD. CyA is administered orally or intravenously (IV). We have experienced unexplainable high blood values in patients receiving oral or IV CyA. Normal practice is to draw blood samples from the CVC. Adherence of CyA to the catheter luminal wall is proposed as the cause during IV infusion and after discontinuing IV infusion of CyA. A prospective study was performed in order to ensure the validity of CyA concentration in blood samples taken from peripheral vene and central venous catheters (CVC) and to define how long CyA is traceable after infusion of CyA in Hickmann catheter lumen. Material (or patients) and methods: Myeloablative HSCT patients were recruited in the period from July 2014 to February 2015 at our bone marrow transplant center. All patients have given informed consent. CyA was analyzed concomitantly from: Peripheral blood (PB), CVC-line never used for CyA infusion (non CyA-Line) and CVC-line used for CyA infusion (CyA-line). All samples from CVC were drawn according to our SOP, which includes discharge of the first 10 ml blood drawn from CVC. All CVC's were three lumen Hickmann catheters. Results: Patients (N = 8) participated in the study of CyA measurements from CyA-line, nonCyA-line and PB measurements. Results from blood samples drawn from CyA-line showed significantly higher values than from non CyA-line and PB. CyA measurements from non CyA-line compared to PB values, showed no significant difference. Patients (N = 8) participated in the study of CyA measurements after IV infusion. We measured CyA concentration from CyA-line, non CyA-line and PB. Result showed significant higher values for CyA-line after discontinuing the IV infusion compared non CyA-line and PB for at least two weeks after discontinuing IV CyA infusion. Conclusion: During IV CyA infusion: Blood samples drawn for CyA analysis from non-CyA-line are comparable to PB values. In contrast, CyA-measurements of blood drawn from CyA-line are significantly higher, despite use of the SOP procedure. After IV infusion (CyA administered orally): CyA values from non-CyA-line are in full correlation with values from PB.
Up till two weeks after last infusion of CyA, blood samples from the CyA-line contain significantly higher levels of CyA. Even two weeks after discontinuing IV CyA there are differences in blood values. During oral intake of CyA (control) Measurements taken from a CVC-line, never used for IV infusion of CyA, compared to samples from PB, are comparable for CyA. We conclude that our practice of using the non-CyA-line for blood concentration measurements is justified. Introduction: After stem cell transplantation, patients normally stay at the hospital for two to three weeks until leucocyte recovery. For a selected group of hematology patients it is possible to spend the neutropenic phase after autologous stem cell transplantation at home. Crucial in this process is a 24 hour available caregiver. Some caregivers experience this as a heavy responsibility and a difficult task, accompanied by many uncertainties. We set up a system of ambulatory care in which patients have a hospital check three times a week supplemented with screen to screen contact via remote video technology. Because this is an innovative intervention, a feasibility study started in July 2015. The aim of this study is to evaluate the use of remote video technology in the home health care setting by judging the technical and visual quality as well as patient, caregiver and nurse satisfaction with this innovation. The study will end when saturation of the data occurs. Material (or patients) and methods: Ten patients and their caregivers were recruited from the St. Antonius Hospital in Nieuwegein in the Netherlands. Patients were provided with a tablet and software. Wi-Fi at the patient's home was required. Twice a week the outpatient team set up a video call with the patient and caregiver, in addition to the ambulatory care provided three times a week. Data were sampled by keeping a logbook. Patient, caregiver and outpatient team outcomes were measured at the end of each session using semistructured questionnaires. Results: All the patients and caregivers perceived both the tablet and communication application as easy to use. Ninety percent of the patients and caregivers were highly satisfied with the screen to screen contact with the ambulatory team. Ninety percent thought screen to screen contact had helped them feel more confident and safe in the ambulatory setting. Ten percent (1/10) did not perceive any added value.
There were only two failed attempts (2/45) to get in contact with patient and caregiver. In all other cases setting up the calls went smoothly. Sound and vision quality turned out to be dependent on the quality of Wi-Fi at the patient's home. The image quality was fairly good, but not good enough to evaluate possible mucositis in the oropharynx. The outpatient team perceived great value to screen to screen contact for carrying out clinical eye assessment of the patient, and for its capability for clinical observation and the empowerment of both patient and caregiver. Conclusion: The majority of patients and caregivers showed high satisfaction with the use of screen to screen contact. Both patients, their caregivers and the outpatient team appreciated screen to screen contact and the added value it gave to guiding patient and caregiver in the ambulatory care phase. The technical and visual quality of the screen to screen contact was experienced as good. The key advantages of this screen to screen contact, as seen by the outpatient team, were enhancement of increasing the patient's and caregiver's confidence while staying at home during the neutropenic phase. Disclosure of Interest: None declared. Introduction: One of the major limit of allogeneic transplants has been the availability of a suitable donor. In Italy the search of unrelated donors (UD) and cord blood units is pursued uniquely through Italian Bone Marrow Donor Registry (IBMDR); this is the only authorized Agency, which all Italian Transplant Centers refer to and its costs are completely paid by the public health care system through the National Registry (IBMDR). A recent survey from the EBMT showed significant national differences in the attitude to use different type of donors. In Italy we observed a significant increase in the prevalence of haplos (28.2% of allotransplants in 2014); we wondered if it could be explained by some specific criticalities in UD search in comparison to other Countries. The aim of the analysis was the evaluation of the probability and the time to find an UD and the costs of adult UD search in Italy. Material (or patients) and methods: We analysed all the UD searches performed in Italy by 55 Centers from January 1 st to June 30 th 2015. Results: 881 searches have been initiated in favour of 879 patients affected by several haematological diseases. They requested 1684 samples on behalf of 746 pts. 1360 samples have been asked to three Registries (ZKRD -705-, IBMDR -331-and NMDP -324-).1108 (65.8%) samples arrived at the HLA labs with significant differences across the Registries (75.5% German, 70.4 Italian, 44.4% USA). 1091 samples have been finally typed and resulted at least 7/8 matched at 3, 6 and 10 months 81.9%, 89.3% and 90.6%, respectively. The median time from search activation to donor identification was 37 days; the median time from search activation to verification typing was 5 days; the median time from verification typing to sample arrival at the HLA lab was 12 days and finally 16 days was the median time needed to perform the typing (HLA-A,B,C DRB1* and DQB1* HR). The 3 month-probability of finding a 8/8 or at least 7/8 matched donor has been 0.4 and 0.7 respectively. Only 41.% (369) of identified donors have been selected for work up and the median time from donor CT results to transplant has been 39 days (1-3 rd quartiles 31-48 Introduction: Microbiological controls done for air quality in critical areas is important for protecting the cellular product from microbial contamination and thereby the patients from infections during transplant process. Therefore air quality in critical areas should be periodically controlled with regard to bacterial and fungal contamination. Different techniques are used for microbiological measurements for air quality. The second samples were obtained using automatic air sampler (RGF Environmental, Florida/USA) since January 2015 in our center. The settle plates method is insufficient for quantitative assessment of the microbiological contamination in a certain air volume. The aim of this study is to determine whether there is a difference between conventional the settle plates method and automatic air sampler with regard to microbiological growing and to validate the new method for our center. Material (or patients) and methods: Two separate samples were obtained from the critical areas and the devices in Cell Processing Unit using the settle plates method and air sampler. In the settle plates method, petri plates were left to air flow for 2 hours and samples were collected. Samples were obtained also using air sampler and all samples were transferred to Microbiology Laboratory for incubation. Results: A total of six samples obtained monthly from the critical areas between January 2015 and June 2015 were evaluated for fungal and bacterial growing. Fungal and bacterial growing did not occur in the samples which were obtained using two methods in January, February and June. Fifty mold colonies were detected in the samples obtained from the incubator with each of two methods in March. One mold colony was detected in the sample obtained from the incubator using the settle plates method in April, in one of each samples obtained from the right of the clean room and quality laboratory in May however no colony was detected in the samples obtained using air sampler device. Bacterial growth was not detected in the samples obtained using both methods. Conclusion: Petri plates are exposed to environmental factors in the settle plates method and this condition leads the other factors than air to increase contamination risk. Introduction: There is much variation in clinical practice and little literature regarding the optimal dose and timing of cyclosporine (CsA) initiation for acute graft versus host disease (aGHVD) prophylaxis. Material (or patients) and methods: To guide the development of consensus guidelines for CsA initiation at our centre, we reviewed information from consecutive recipients of allogeneic HSCT at our centre who received methotrexate and CsA GVHD prophylaxis and achieved neutrophil recovery between January 2004 and August 2015. Methotrexate was given at 15 mg/m 2 IV on day +1 and 10 mg/m 2 on day +3, +6 and +11. CsA was commenced at 1.5 mg/kg twice daily as an IV infusion and titrated to achieve a target trough level of 200-300 μg/L, with routine levels taken every Monday, Wednesday and Friday. Results: A total of 207 recipients of myeloablative (n = 171) and reduced intensity (n = 36) allogeneic HSCT were included. CsA was commenced on transplant day -1 (n = 93) or earlier (n = 109, 5 cases missing data) depending on physician preference. Antifungal prophylaxis was with fluconazole alone (n = 171) or another agent (n = 30, 6 cases missing data). Trough CsA levels are summarised in the Table. CsA levels (4 200 μg/L) were achieved in 12% of patients by day +3 and 42% of patients by day+5, while 26% had low CsA levels ( o100 μg/L) by day +3 and 5% by day +5. The type of antifungal prophylaxis used did not correlate with the achievement of target CsA levels at any of the time points measured (Fisher's exact test). The cumulative incidence of grade II-IV aGVHD was 56% by day 180 (95% confidence interval (CI) 49-62%). Neither the timing of CsA initiation (day -1 versus earlier) nor the CsA level by day +3 or day +5, nor time to achieve target CsA levels were associated with the risk of aGHVD (Cox regression). Interestingly, patients with low ( o100 μg/L) CsA levels by day +3 had a lower risk of grade II-IV aGVHD (HR 0.60, 95% CI 0.38-0.95, P = 0.029). On multivariate analysis adjusting for donor type (related versus unrelated) and conditioning regimen intensity, early CsA level o100 μg/L was independently associated with a lower risk of aGVHD (HR 0.61, 95% CI 0.38-0.97, P = 0.035).
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Trough CsA level
Median Range Time to achieve target cyclosporine level (from commence-
Trough CsA levels after stem cell infusion
At a uniform starting dose of 1.5 mg/kg twice daily IV, target CsA levels were only reached after a median 8 days of therapy. However, earlier achievement of target CsA levels did not infer a lower risk of aGVHD. Rather, patients with low CsA levels very early after transplant had a lower risk of aGVHD, independent of conventional GVHD risk factors. While this observation requires replication and further investigation, our analysis provides no rationale for more intensive initiation of CsA after allogeneic HSCT. With intense competition for hospital resources to evaluate and manage patients preparing for stem cell mobilization and transplantation, analysis of resource utilization is warranted. Plerixafor (P) is indicated in combination with G-CSF to enhance mobilization of hematopoietic stem cells to the peripheral blood (PBSC) for collection, and subsequent autologous transplantation in patients with NHL and MM whose cells mobilize poorly; P has demonstrated significant impact on mobilization results. Material (or patients) and methods: A non-interventional 2-part study using aggregated, de-identified data was conducted to analyze impact of plerixafor on efficiency of hematological department in hospitals associated with PBSC mobilization and apheresis in NHL patients in era prior to and following approval of plerixafor (to the "Pre-P" era through June 1, 2009, and "P" era from July 1, 2010 onwards; "P", respectively). Adult patients ≥ 18 years, with primary diagnosis of NHL, who underwent PBSC mobilization at 9 European centers in France, Germany and Italy were included (n = 248). Part I: Retrospective medical record review of identified NHL patients. Outcomes measured in Part I included # visits for administration of mobilizing agents and # days administered; assessment of adverse events (AEs); # apheresis sessions; hrs of apheresis sessions; attainment of CD34+ target; and days until CD 34+ target level met. For Pre-P era patients, peripheral CD-34+ count was recorded immediately prior to first apheresis; for P era patients, it was recorded immediately prior to plerixafor administration. Part II: Prospective time and motion evaluation of apheresis performed at each center; patient consent was obtained). Time-motion assessments, obtained retrospectively(Part I) & prospectively(Part II), included total time to prepare patient, perform apheresis and manage AEs. Micro-costing was conducted by obtaining costs per unit of resource utilization from interviews with hospital staff. Study end points are difference in mean time/ effort to perform apheresis (including apheresis related AEs and total costs associated with mobilization to hospital between patients in Pre-P versus P eras. Results: No significant demographic differences were found between pre-P and P era cohorts. Analysis of # apheresis sessions demonstrated statistically significant reduction (Po0.001) for P era group, including # of sessions, total blood volume collected and total apheresis time required to reach targeted PBSC compared with Pre-P era group. Total cost differences between cohorts was estimated based on observed clinical and resource utilization differences. More than twice as many patients who had a CD 34+ o10 were mobilized in P era compared with patients in Pre-P era. Conclusion: Final results of this study demonstrates that use of plexiafor is associated with statistically significant reductions in the # apheresis sessions, driving both resource utilization efficiencies and cost savings for NHL patients undergoing autologous PBSC mobilization vs patients in pre-P era. Further research to quantify the time and motion and cost-consequences of treatment approaches for stem cell mobilization in routine clinical care is warranted to optimize treatment for NHL patients. Disclosure of Interest: None declared. Conclusion: A significant reduction in acquisitions was seen from November 2014; due to the large number of interventions introduced it has been difficult to identify a single intervention as being responsible for the dramatic decline in acquisitions. All the interventions remain in place with regular monitoring and review, it has now been 6 months since last acquision on ward 44. Disclosure of Interest: None declared.
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